Stock listing
Dusseldorf:PBS0 Precision BioSciences, Inc. Aktie
German listing (Dusseldorf) of Precision BioSciences, Inc. · home listing NASDAQ:DTIL
Follow Precision BioSciences, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:DTIL
$7.40 USD +0.30 (+4.2%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:DTIL
- Day range
- $6.77 – $7.55 USDNov 20, 2026
- Volume
- 429,792 sharesNov 20, 2026
- Market cap
- $282.5M USDAt the close on Nov 20, 2026 · price × 38.17M shares outstanding
- 52-week range
- $3.53 – $11.29 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $2.52M USDMedian day 251,718 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:DTIL · Home | $7.40 USD | +0.30 (+4.2%) | 429,792 | $6.77 | $7.55 | $6.77 | $7.10 | Close on Nov 20, 2026 |
| Frankfurt:PBS0 | €5.76 EUR | -0.24 (-4.0%) | — | €6.19 | €6.19 | €5.76 | €6.00 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:DTIL · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $7.40 | +0.30 | +4.2% | $6.77 | $7.55 | $6.77 | 429,792 | |
| $7.10 | +0.05 | +0.7% | $6.94 | $7.39 | $6.94 | 370,311 | |
| $7.05 | -0.23 | -3.2% | $7.26 | $7.46 | $6.88 | 350,990 | |
| $7.28 | -0.285 | -3.8% | $7.52 | $7.635 | $7.25 | 204,411 | |
| $7.565 | -0.475 | -5.9% | $8.15 | $8.16 | $7.525 | 394,619 | |
| $8.04 | -1.11 | -12.1% | $8.97 | $9.00 | $7.972 | 414,048 | |
| $9.15 | -0.35 | -3.7% | $9.46 | $9.585 | $8.93 | 251,718 | |
| $9.50 | -0.18 | -1.9% | $9.57 | $10.02 | $9.22 | 352,757 | |
| $9.68 | -0.92 | -8.7% | $10.72 | $10.80 | $9.615 | 589,692 | |
| $10.60 | +0.73 | +7.4% | $9.80 | $10.78 | $9.07 | 1,228,661 | |
| $9.87 | +1.75 | +21.6% | $8.49 | $11.29 | $8.40 | 2,911,977 | |
| $8.12 | +1.15 | +16.5% | $7.205 | $8.13 | $7.14 | 400,518 | |
| $6.97 | +0.02 | +0.3% | $6.95 | $7.186 | $6.64 | 144,825 | |
| $6.95 | -0.11 | -1.6% | $7.06 | $7.42 | $6.82 | 167,793 | |
| $7.06 | -0.38 | -5.1% | $7.31 | $7.42 | $6.98 | 108,829 | |
| $7.44 | -0.03 | -0.4% | $7.50 | $7.82 | $7.37 | 165,713 | |
| $7.47 | +0.68 | +10.0% | $6.76 | $7.50 | $6.66 | 189,294 | |
| $6.79 | +0.38 | +5.9% | $6.39 | $6.81 | $6.29 | 164,247 | |
| $6.41 | -0.23 | -3.5% | $6.68 | $6.876 | $6.37 | 266,677 | |
| $6.64 | -0.14 | -2.1% | $6.73 | $6.73 | $6.29 | 275,388 | |
| $6.78 | +0.07 | +1.0% | $6.70 | $6.925 | $6.58 | 132,428 | |
| $6.71 | +0.15 | +2.3% | $6.62 | $6.86 | $6.545 | 231,040 | |
| $6.56 | +0.37 | +6.0% | $6.09 | $6.67 | $6.09 | 213,655 | |
| $6.19 | +0.42 | +7.3% | $5.80 | $6.21 | $5.77 | 176,469 | |
| $5.77 | -0.40 | -6.5% | $6.18 | $6.18 | $5.72 | 300,200 | |
| $6.17 | +0.14 | +2.3% | $6.04 | $6.20 | $5.98 | 246,100 | |
| $6.03 | -0.07 | -1.1% | $6.05 | $6.25 | $5.92 | 294,200 | |
| $6.10 | -0.43 | -6.6% | $6.51 | $6.55 | $6.05 | 326,700 | |
| $6.53 | -0.19 | -2.8% | $6.71 | $6.729 | $6.448 | 228,800 | |
| $6.72 | +0.29 | +4.5% | $6.43 | $6.92 | $6.35 | 263,700 | |
| $6.43 | +0.18 | +2.9% | $6.25 | $6.53 | $6.19 | 332,500 | |
| $6.25 | +0.05 | +0.8% | $6.20 | $6.38 | $6.11 | 162,500 | |
| $6.20 | -0.11 | -1.7% | $6.36 | $6.40 | $6.105 | 191,000 | |
| $6.31 | 0.00 | 0.0% | $6.36 | $6.375 | $5.975 | 218,800 | |
| $6.31 | -0.02 | -0.3% | $6.42 | $6.44 | $6.20 | 293,000 | |
| $6.33 | +0.07 | +1.1% | $6.33 | $6.47 | $6.24 | 242,200 | |
| $6.26 | +0.08 | +1.3% | $6.24 | $6.40 | $6.14 | 249,200 | |
| $6.18 | -0.06 | -1.0% | $6.37 | $6.45 | $6.08 | 154,100 | |
| $6.24 | +0.02 | +0.3% | $6.21 | $6.255 | $6.00 | 222,800 | |
| $6.22 | -0.11 | -1.7% | $6.35 | $6.55 | $6.18 | 204,000 | |
| $6.33 | -0.03 | -0.5% | $6.31 | $6.465 | $6.18 | 401,800 | |
| $6.36 | -0.83 | -11.5% | $7.16 | $7.17 | $6.34 | 355,900 | |
| $7.19 | +0.69 | +10.6% | $6.57 | $7.313 | $6.55 | 431,600 | |
| $6.50 | -0.17 | -2.5% | $6.73 | $6.75 | $6.44 | 272,300 | |
| $6.67 | 0.00 | 0.0% | $6.65 | $6.87 | $6.57 | 240,400 | |
| $6.67 | +0.04 | +0.6% | $6.77 | $6.923 | $6.41 | 373,900 | |
| $6.63 | +0.02 | +0.3% | $6.65 | $6.82 | $6.53 | 289,200 | |
| $6.61 | -0.25 | -3.6% | $6.86 | $6.90 | $6.48 | 314,600 | |
| $6.86 | -0.31 | -4.3% | $7.13 | $7.255 | $6.85 | 236,300 | |
| $7.17 | -0.07 | -1.0% | $7.28 | $7.38 | $7.06 | 191,400 | |
| $7.24 | -0.01 | -0.1% | $7.16 | $7.27 | $7.035 | 143,400 | |
| $7.25 | -0.15 | -2.0% | $7.38 | $7.49 | $7.15 | 273,500 | |
| $7.40 | -0.07 | -0.9% | $7.41 | $7.49 | $7.20 | 139,900 | |
| $7.47 | +0.10 | +1.4% | $7.32 | $7.575 | $7.32 | 124,200 | |
| $7.37 | -0.08 | -1.1% | $7.48 | $7.55 | $7.23 | 187,000 | |
| $7.45 | -0.19 | -2.5% | $7.66 | $7.82 | $7.24 | 358,900 | |
| $7.64 | 0.00 | 0.0% | $7.54 | $7.68 | $7.49 | 170,900 | |
| $7.64 | -0.14 | -1.8% | $7.75 | $7.80 | $7.493 | 214,800 | |
| $7.78 | -0.62 | -7.4% | $8.37 | $8.43 | $7.72 | 222,300 | |
| $8.40 | -0.09 | -1.1% | $8.54 | $8.54 | $8.21 | 274,800 | |
| $8.49 | -0.06 | -0.7% | $8.58 | $8.66 | $8.33 | 262,700 | |
| $8.55 | +0.10 | +1.2% | $8.43 | $8.75 | $8.33 | 418,200 | |
| $8.45 | -0.40 | -4.5% | $8.82 | $8.82 | $8.36 | 232,700 | |
| $8.85 | +0.13 | +1.5% | $8.81 | $9.08 | $8.63 | 305,200 | |
| $8.72 | +0.22 | +2.6% | $8.60 | $9.34 | $8.59 | 496,300 |
Splits
1 split · NASDAQ:DTIL · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-30 | Consolidation |
- Ticker
- Dusseldorf:PBS0
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Dusseldorf
- Currency
- EUR
What changed lately
Latest news release · Nov 20, 2026
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Latest deck · Nov 5, 2026
AASLD 2026
Conference · 74 slides
Latest news
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Nov 20, 2026
Closed $7.40 (+4.2%) on Nov 20, 2026
Precision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Nov 5, 2026
Closed $9.87 (+21.6%) on Nov 5, 2026
Precision BioSciences Announces Positive DSMB Safety Review Supporting Additional PBGENE-DMD Dosing in Phase 1/2 FUNCTION-DMD Study
Nov 5, 2026
Closed $9.87 (+21.6%) on Nov 5, 2026
Precision BioSciences Announces Late-Breaking PBGENE-HBV Data at AASLD The Liver Meeting® 2026 Further Demonstrating cccDNA Elimination and Potential to Drive Viral Cure
Nov 5, 2026
Closed $9.87 (+21.6%) on Nov 5, 2026
Precision BioSciences Reports Third Quarter 2026 Financial Results and Provides Business Update
Nov 3, 2026
Closed $6.97 (+0.3%) on Nov 3, 2026
Precision BioSciences to Report Third Quarter 2026 Financial Results on November 3, 2026
Oct 29, 2026
Closed $7.44 (-0.4%) on Oct 29, 2026
Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting 2026
Oct 8, 2026
Closed $6.43 (+2.9%) on Oct 8, 2026
Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study
Aug 24, 2026
Closed $8.45 (-4.5%) on Aug 24, 2026
Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Aug 6, 2026
Closed $7.42 (-0.7%) on Aug 6, 2026
Precision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026
Jul 31, 2026
Closed $6.99 (-0.1%) on Jul 31, 2026
Precision BioSciences, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 31 in the last 12 months · 199 in all · newest Nov 20, 2026 · oldest 2019
- Decks
- 54 decks · latest Nov 5, 2026
Where Precision BioSciences, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:DTIL · Home listing | NASDAQ | United States | USD |
| gettex:PBS0 | gettex | Germany | EUR |
| LS Exchange:A400AS | LS Exchange | Germany | EUR |
| Lang & Schwarz:A400AS | Lang & Schwarz | Germany | EUR |
| Stuttgart:PBS0 | Stuttgart | Germany | EUR |
| BOATS:DTIL | BOATS | United States | USD |
| Frankfurt:PBS0 | Frankfurt | Germany | EUR |
| Dusseldorf:PBS0 · This page | Dusseldorf | Germany | EUR |
| Hamburg:PBS0 | Hamburg | Germany | EUR |
| Munich:PBS0 | Munich | Germany | EUR |
| Tradegate:PBS0 | Tradegate | Germany | EUR |
Valuation
EV/sales 5.1× against a median of 467×: the lowest of 2 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $228.3M USD
- P/E
- Loss
- EV/sales
- 5.1×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 5.5×
- Gross margin
- Not reported
- Operating margin
- −80.3%
- Net margin
- −85.6%
- Debt to equity
- 0.5×
- Beta vs S&P 500
- 0.30
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Precision BioSciences, Inc. · NASDAQ:DTIL | US$282.5M | US$228.3M | n/a | 5.1× | n/a | 5.5× | −85.6% | 0.5× | 0.30 |
| Contineum Therapeutics, Inc. · NASDAQ:CTNM | US$286.1M | US$47.86M | n/a | n/a | n/a | 1.2× | n/a | 0.0× | 1.53 |
| TRex Bio, Inc. · NASDAQ:TRXB | US$283.1M | US$205.0M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Greenwich LifeSciences, Inc. · NASDAQ:GLSI | US$282.6M | US$276.7M | n/a | n/a | n/a | n/a | n/a | n/a | 2.80 |
| AP Biosciences, Inc. · TPEX:6945 | US$282.3M | US$215.7M | n/a | n/a | n/a | 4.0× | n/a | 0.0× | n/a |
| Fulcrum Therapeutics, Inc. · NASDAQ:FULC | US$281.8M | −US$17.87M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 0.42 |
| Circio Holding ASA · OSL:CRNA | US$281.0M | US$225.8M | n/a | n/a | n/a | 5.3× | n/a | 0.0× | n/a |
| Relmada Therapeutics, Inc. · NASDAQ:RLMD | US$279.5M | US$77.42M | n/a | n/a | n/a | 1.4× | n/a | 0.0× | 1.57 |
| Benitec Biopharma Inc. · NASDAQ:BNTC | US$276.1M | US$99.78M | n/a | n/a | n/a | 1.6× | n/a | 0.0× | 1.46 |
| Galectin Therapeutics Inc. · NASDAQ:GALT | US$271.4M | US$293.0M | n/a | n/a | n/a | n/a | n/a | n/a | 1.20 |
| Vicore Pharma Holding AB · OMXSTO:VICO | US$271.2M | US$182.6M | n/a | 467× | n/a | 3.3× | n/a | 0.0× | n/a |
| Median of the others | US$281.4M | US$193.8M | 467× | 1.6× | 0.0× | 1.50 |
Forecasts
5 strong buy · Analysts' consensus from EODHD, read Nov 16, 2026. Not 6ix's view and not investment advice.
- Price target
- 29.40 USD · Analysts' mean
- EPS, year to Dec 2026
- -2.85 · 4 analysts
- Revenue, year to Dec 2026
- 11.35M · 5 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Michael Amoroso | President, Chief Executive Officer |
| Naresh Tanna | Chief Financial Officer |
| Alex Kelly | Chief Operating Officer |
| Dario Scimeca | Chief Legal Officer |
| Neil Leatherbury | Senior Vice President of Chemistry, Manufacturing, and Controls (CMC) |
| Cassie Gorsuch | Chief Scientific Officer |
| Cindy Atwell | Chief Development Officer |
| Jeff Smith | Chief Research Officer |
| Juli Blanche | Chief People Officer |
| Mark Sulkowski | Head Clinical Development Advisor |
Board
| Director |
|---|
| Geno Germano |
| Shari Lisa Piré |
| Stanley Frankel |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 3, 2026 · Before open | +0.3% |
| Q2 2026 | Aug 6, 2026 · Before open | −0.7% |
| Q1 2026 | May 5, 2026 · Before open | −2.4% |
| Q4 2025 | Mar 12, 2026 | +12.1% |
| Q3 2025 | Nov 3, 2025 · Before open | −9.8% |
| Q2 2025 | Aug 7, 2025 · Before open | −5.0% |
| Q1 2025 | May 15, 2025 · Before open | −8.1% |
| Q4 2024 | Mar 25, 2025 · Before open | −9.8% |
| Q3 2024 | Nov 4, 2024 · Before open | −8.1% |
| Q2 2024 | Aug 1, 2024 · Before open | +0.4% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 13, 2024 · Before open | +8.1% |
| Q4 2023 | Mar 27, 2024 · Before open | +1.8% |
| Q3 2023 | Nov 7, 2023 · Before open | −2.5% |
| Q2 2023 | Aug 4, 2023 · Before open | +3.9% |
| Q1 2023 | May 9, 2023 · Before open | 0.0% |
| Q4 2022 | Mar 9, 2023 · Before open | −11.3% |
| Q3 2022 | Nov 8, 2022 · Before open | +2.4% |
| Q2 2022 | Aug 8, 2022 · Before open | −7.5% |
| Q1 2022 | May 9, 2022 · Before open | −9.8% |
| Q4 2021 | Mar 15, 2022 · Before open | −16.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| AASLD 2026 | Conference | 74 slides | Nov 5, 2026 |
| Investor Presentation (November 2026) | Investor deck | 76 slides | November 2026 |
| Investor Presentation (August 2026) | Investor deck | 53 slides | August 2026 |
| Technical Presentation (May 2026) | Technical | 58 slides | May 27, 2026 |
| Corporate Update (March 2026) | Corporate update | 45 slides | Mar 17, 2026 |
| Investor Presentation (January 2026) | Investor deck | 33 slides | January 2026 |
| AASLD 2025 | Conference | 19 slides | Nov 10, 2025 |
| Corporate Update (November 2025) | Corporate update | 43 slides | November 2025 |
| Investor Presentation (September 2025) | Investor deck | 44 slides | September 2025 |
| Investor Presentation (May 2025) | Investor deck | 56 slides | May 2025 |
Show 50 decks
This page holds 50 of 54 decks. Open Decks
Financings
| Raise | Date |
|---|---|
| Public offering of common stock and pre-funded warrants Announced: about US$125M · US$7.75 a share · TD Cowen +1 Dealers: TD Cowen (co-lead), Guggenheim Securities (co-lead) Buyers: First Light Asset Management; MPM BioImpact; Bleichroeder LP; Lynx1 Capital Management; Readout Capital; Aberdeen Investments; Driehaus Capital Management Use of proceeds: Continued research and development of PBGENE-HBV and PBGENE-DMD, working capital and general corporate purposes | Nov 5, 2026 |
| Strategic investment of common stock Announced: US$2.25M · US$11.17 a share Buyers: TG Therapeutics, Inc. ($2.25 million for 201,504 shares of common stock at $11.17 per share) Use of proceeds: Supports cash runway through 2028 and focus on in vivo gene editing pipeline | Mar 2, 2026 |
| Public offering of common stock, pre-funded warrants and warrants Announced: about US$75M · US$6.14 a share · ½ warrant at US$7.25 for 60 months · Guggenheim Securities Dealers: Guggenheim Securities (lead) Buyers: Aberdeen Investments; Bleichroeder LP; Driehaus Capital Management; Empery Asset Management LP; Lynx1 Capital Management; Octagon Capital; Readout Capital; Sphera Funds Management; Stonepine Capital Management Use of proceeds: Ongoing and planned research and development, working capital and general corporate purposes | Nov 10, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$16.00 a share on Mar 27, 2019.
- Price
- US$16.00 a share
- Shares offered
- 7,900,000 shares of common stock
- Offering size
- US$126.4 million
- Underwriters' option
- Up to 1,185,000 more shares
- Underwriters
- J.P. Morgan, Goldman Sachs & Co. LLC, Jefferies, Barclays · In the order on the cover
- Shares delivered
- On or about Apr 1, 2019
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Oct 19, 2018 |
| Filed publicly | Mar 1, 2019 |
| Amended twice | Newest Mar 18, 2019 |
| Shares registered with an exchange | Mar 19, 2019 |
| Declared effective by the SEC | Mar 27, 2019 |
| Final prospectus, with the price | Mar 28, 2019 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Mar 28, 2019 |
| EFFECT · Notice that a registration is effective | Mar 27, 2019 |
| CORRESP · Letter to the SEC | Mar 25, 2019 |
| CORRESP · Letter to the SEC | Mar 25, 2019 |
| CERT · Exchange's certificate of listing | Mar 25, 2019 |
| 8-A12B · Registration of shares for listing on an exchange | Mar 19, 2019 |
| UPLOAD · Letter from the SEC | Mar 18, 2019 |
| S-1/A · Registration statement, amended | Mar 18, 2019 |
| CORRESP · Letter to the SEC | Mar 13, 2019 |
| S-1/A · Registration statement, amended | Mar 13, 2019 |
All 20 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Mar 8, 2019 |
| UPLOAD · Letter from the SEC | Mar 6, 2019 |
| S-1 · Registration statement | Mar 1, 2019 |
| UPLOAD · Letter from the SEC | Feb 22, 2019 |
| DRSLTR · Letter to the SEC with a draft | Feb 21, 2019 |
| DRS/A · Draft registration statement, amended | Feb 21, 2019 |
| DRSLTR · Letter to the SEC with a draft | Dec 28, 2018 |
| DRS/A · Draft registration statement, amended | Dec 28, 2018 |
| UPLOAD · Letter from the SEC | Nov 16, 2018 |
| DRS · Draft registration statement | Oct 19, 2018 |
Open IPO · From the cover of the final prospectus (424B4) filed Mar 28, 2019
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 34.3M | 68.7M | 48.7M | 25.1M | 115.5M | 24.3M | 1.07B | 10.9M | 6.48M | 7.01M |
| Cost of revenue | 2.75M | 4.58M | 8.26M | 9.00M | 0 | 0 | 0 | |||
| Gross profit | 34.3M | 68.7M | 48.7M | 25.1M | 115.5M | 24.3M | 22.2M | 10.9M | 6.48M | 7.01M |
| Research and development | 54.2M | 59.6M | 53.4M | 46.1M | 115.2M | 98.1M | 82.4M | 45.1M | 20.3M | 9.10M |
| Selling, general and administrative | 32.2M | 35.3M | 39.1M | 41.3M | 39.7M | 36.1M | 27.0M | 13.7M | 8.02M | 6.17M |
| Operating income | -52.1M | -26.2M | -43.7M | -62.3M | -39.4M | -109.8M | -87.2M | -47.9M | -22.0M | -8.83M |
| Depreciation and amortization | 1.47M | 3.40M | 6.82M | 7.80M | 8.98M | 8.78M | 5.32M | 2.35M | 1.44M | 640.0K |
| EBITDA | -50.7M | -22.8M | -36.9M | -54.5M | -30.4M | -101.1M | -81.9M | -45.6M | -20.5M | -8.19M |
| Interest expense | 1.42M | 1.78M | 2.23M | 1.11M | 132.0K | 822.0K | 182.0K | 0 | 0 | 0 |
| Income before tax | -45.7M | 7.17M | -42.5M | -72.9M | -30.6M | -109.0M | -92.9M | -46.0M | -21.1M | -8.26M |
| Income tax | 0 | 0 | 27.2M | 11.3M | 316.0K | 23.0K | -9.58M | 1.88M | -754.0K | -5.00K |
| Net income | -45.7M | 7.17M | -61.3M | -111.6M | -30.6M | -109.0M | -92.9M | -46.0M | -21.1M | -8.25M |
| Earnings per share, basic | -3.56 | 1.05 | -15.96 | -38.10 | -0.52 | -2.09 | -2.21 | -2.92 | -18.81 | -0.49 |
| Earnings per share, diluted | -3.56 | 1.04 | -15.96 | -38.10 | -0.52 | -2.09 | -2.21 | -2.92 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 110.8M | 85.9M | 116.7M | 189.6M | 143.7M | 89.8M | 180.9M | 103.2M | 62.8M | 93.4M |
| Short-term investments | 4.76M | 413.0K | 0 | |||||||
| Receivables | 0 | 229.0K | 901.0K | 720.0K | 488.0K | 10.0M | 965.0K | 523.0K | 22.0K | 386.0K |
| Inventory | 7.55M | 17.4M | 5.76M | 9.50M | ||||||
| Current assets | 118.7M | 95.0M | 136.4M | 199.1M | 161.8M | 105.6M | 193.7M | 115.7M | 64.3M | 94.4M |
| Property, plant and equipment | 1.43M | 3.09M | 6.34M | 11.8M | 25.2M | 35.1M | 39.6M | 21.1M | 8.14M | 3.54M |
| Total assets | 154.4M | 136.4M | 159.8M | 238.2M | 211.5M | 150.2M | 235.2M | 138.6M | 72.7M | 98.4M |
| Accounts payable | 296.0K | 1.31M | 2.97M | 653.0K | 1.14M | 792.0K | 2.04M | 2.22M | 1.81M | 1.29M |
| Current liabilities | 8.91M | 15.0M | 50.0M | 59.7M | 36.0M | 42.8M | 26.9M | 14.1M | 9.20M | 8.34M |
| Long-term debt | 22.4M | 22.3M | 22.2M | 2.48M | ||||||
| Total debt | 28.8M | 30.0M | 31.3M | 22.2M | 2.48M | 10.5M | ||||
| Total liabilities | 62.2M | 80.0M | 140.9M | 177.7M | 120.3M | 105.7M | 96.9M | 98.6M | 99.1M | 103.2M |
| Shareholders' equity | 92.2M | 56.4M | 18.9M | 60.4M | 91.2M | 44.4M | 138.3M | 40.0M | -26.4M | -4.75M |
| Shares outstanding | 24.1M | 8.20M | 4.16M | 3.70M | 60.9M | 52.7M | 51.2M | 15.9M | 1.12M | 16.7M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -65.8M | -58.4M | -84.1M | -45.8M | -10.9M | -87.4M | -71.0M | -51.7M | -24.2M | 92.3M |
| Capital spending | -85.0K | -250.0K | -1.96M | -3.32M | -5.05M | -5.03M | -24.7M | -14.3M | -5.57M | -2.08M |
| Free cash flow | -65.9M | -58.7M | -86.1M | -49.1M | -15.9M | -92.4M | -95.7M | -66.0M | -29.7M | 90.2M |
| Cash from investing | -634.0K | -215.0K | 5.83M | -3.32M | -5.80M | -5.03M | -24.7M | -15.7M | -5.51M | -2.08M |
| Cash from financing | 95.2M | 50.5M | 5.39M | 95.0M | 70.5M | 1.33M | 173.4M | 107.8M | -937.0K | -12.4M |
| Dividends paid | -12.4M | |||||||||
| Share buybacks | 74.7M | 67.3M | 689.0K | 136.4M | 0 | -952.0K | 49.0K | |||
| Change in cash | 28.7M | -8.21M | -72.9M | 45.9M | 53.9M | -91.1M | 77.7M | 40.4M | -30.6M | 77.8M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 10, 2026 | Other filings | SEC |
| 8-K · Current report | Nov 9, 2026 | Current report | SEC |
| 144 · Notice of proposed sale | Nov 6, 2026 | Other filings | SEC |
| 8-K · Current report | Nov 6, 2026 | Current report | SEC |
| 424B5 · Prospectus | Nov 5, 2026 | Offer document | SEC |
| 144 · Notice of proposed sale | Nov 5, 2026 | Other filings | SEC |
| FWP · Free writing prospectus | Nov 5, 2026 | Offer document | SEC |
| 8-K · Current report | Nov 5, 2026 | Current report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 3, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 3, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 3, 2026 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 27, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 29, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 24, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Aug 24, 2026 | Current report | SEC |
| S-8 · Registration statement for employee plans | Aug 7, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| 3 · Initial statement of ownership | Aug 3, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 3, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 3, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 29, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jul 27, 2026 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 20, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jul 1, 2026 | Current report | SEC |
| 8-K · Current report | Jun 16, 2026 | Material contract | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 8-K · Current report | May 27, 2026 | Current report | SEC |
| 8-K · Current report | May 26, 2026 | Management or board change | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | May 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 5, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 15, 2026 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 8, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 8, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 8, 2026 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Mar 27, 2026 | Meeting notice | SEC |
| 8-K · Current report | Mar 17, 2026 | Current report | SEC |
| 10-K · Annual report | Mar 12, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 12, 2026 | Results | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 18, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 11, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 10, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 27, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 22, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 22, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Jan 21, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 21, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 21, 2026 | Other filings | SEC |
| 8-K · Current report | Jan 13, 2026 | Results | SEC |
| EFFECT · Notice that a registration is effective | Jan 8, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 5, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jan 2, 2026 | Other filings | SEC |
| S-3 · Registration statement | Dec 30, 2025 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Dec 30, 2025 | Offer document | SEC |
| 4 · Change in ownership | Dec 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 17, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 12, 2025 | Current report | SEC |
| 424B5 · Prospectus | Nov 12, 2025 | Offer document | SEC |
| FWP · Free writing prospectus | Nov 10, 2025 | Offer document | SEC |
| 8-K · Current report | Nov 10, 2025 | Current report | SEC |
| 4 · Change in ownership | Nov 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 4, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 3, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 3, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 3, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 3, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 3, 2025 | Results | SEC |
| 4 · Change in ownership | Sep 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 24, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 2, 2025 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 6, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 6, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Aug 6, 2025 | Current report | SEC |
| 4 · Change in ownership | Jul 8, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 3, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jun 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 3, 2025 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| 8-K · Current report | May 15, 2025 | Results | SEC |
| 10-Q · Quarterly report | May 15, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 25, 2025 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 15, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 15, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 15, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 4, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 27, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 26, 2025 | Big-stake notice | SEC |
| 424B5 · Prospectus | Mar 26, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 26, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 26, 2025 | Results | SEC |
| 4 · Change in ownership | Mar 25, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 24, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 18, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Mar 7, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 5, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 4, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 4, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 29, 2025 | Management or board change | SEC |
| 144 · Notice of proposed sale | Jan 24, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jan 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 22, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 22, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 21, 2025 | Other filings | SEC |
| 8-K · Current report | Jan 8, 2025 | Results | SEC |
| 4 · Change in ownership | Jan 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 5, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 4, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 4, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 4, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2024 | Results | SEC |
| 8-K · Current report | Oct 24, 2024 | Results | SEC |
| 8-K · Current report | Sep 12, 2024 | Management or board change | SEC |
| 8-K · Current report | Sep 3, 2024 | Current report | SEC |
| 4 · Change in ownership | Aug 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 23, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 1, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 1, 2024 | Results | SEC |
| S-8 · Registration statement for employee plans | Jul 1, 2024 | Offer document | SEC |
| 4 · Change in ownership | Jun 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 10, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 10, 2024 | Other filings | SEC |
| 8-K · Current report | Jun 10, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Jun 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2024 | Insider trade | SEC |
This page holds 200 of 611 filings. Open Filings
Cap table
Built by 6ix from Precision BioSciences, Inc.’s releases · as of Nov 16, 2026
- Common shares
- 38,170,796
- Fully diluted
- 38,249,088
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 38,170,796 | |
| Options and RSUs | 78,292 | Nov 16, 2026 |
Warrants and options
| Lot |
|---|
| RSUs · expiry not stated |
| RSUs · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 38,170,796 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Shalini Sharp Other companies: Iambic Therapeutics, Inc. (Board Member · Since at least Nov 5, 2026); BeOne Medicines Ltd. Class A (Director · Since at least Jun 11, 2026); Septerna, Inc. (Director · Since at least Oct 24, 2024); Organon & Co. (Director · Since at least May 14, 2021); Neurocrine Biosciences, Inc. (Director · Since at least Feb 1, 2020); Nuvation Bio Inc. (Director · Jun 30, 2020 – Feb 10, 2021 · Past); Sutro Biopharma, Inc. (Director · Nov 8, 2018 – Jun 6, 2022 · Past); Ultragenyx Pharmaceutical Inc. (EVP, Finance · Jan 30, 2014 – Oct 14, 2020 · Past); Agenus Inc. (Director · Oct 1, 2006 – Mar 2, 2018 · Past) | Director · Mar 27, 2019 – May 10, 2021 · Past |
| Geno Germano Other companies: Harmony Biosciences Holdings, Inc. (Director · Since at least Apr 2, 2026); Entera Bio Ltd. (Chairman of the Board · Since at least Feb 4, 2026); Sage Therapeutics Inc (Director · Since at least Jun 6, 2018); Bioverativ Inc (Director · Jan 31, 2018 – Mar 8, 2018 · Past); The Medicines Company (Director · Nov 9, 2017 – Jan 6, 2020 · Past) | Director · Since at least Mar 10, 2020 |
| Robert J Adelman Other companies: Metacrine Inc (Director · Sep 15, 2020 – Sep 18, 2020 · Past); Aryx Therapeutics Inc (Director · Nov 7, 2007 – Nov 14, 2008 · Past); Volcano Corp (Director · Jun 14, 2006 – Jun 20, 2006 · Past) | Director · Mar 27, 2019 – Apr 1, 2019 · Past |
| Alan F. List Other companies: TuHURA Biosciences, Inc. (Director · Since at least Oct 18, 2024) | Chief Medical Officer · Apr 26, 2021 – May 1, 2024 · Past |
| Christopher Heery Other companies: Arcellx Inc (CHIEF MEDICAL OFFICER · Since at least Feb 3, 2022) | Chief Medical Officer · Sep 30, 2019 – Jun 8, 2020 · Past |
| John Alexander Kelly Other companies: Forest Laboratories Inc (SVP - Chief Comm's & IR · Oct 24, 2013 – Jun 30, 2014 · Past) | Chief Financial Officer · Since at least Jan 1, 2021 |
| Melinda Brown Other companies: Tapestry, Inc. (SVP, Controller and PAO · Aug 20, 2016 – Aug 17, 2018 · Past) | Director · Since at least May 26, 2022 |
| Michael Amoroso Other companies: Abeona Therapeutics Inc. (Director · Since at least Oct 26, 2020) | President, Chief Executive Officer · Since at least Oct 15, 2021 |
| Raymond F Schinazi Other companies: Cocrystal Pharma, Inc. (Director · Nov 25, 2014 – Sep 21, 2018 · Past) | Director · Mar 27, 2019 – May 10, 2022 · Past |
| Samuel C Wadsworth Other companies: Dimension Therapeutics (Chief Scientific Officer · Oct 21, 2015 – Nov 7, 2017 · Past) | Director · Nov 8, 2021 – Jun 4, 2024 · Past |
All 32 people
| Person | Seat |
|---|---|
| Shane Barton Other companies: BioAge Labs, Inc. (SVP, Finance · Since at least Sep 25, 2024) | VP & Corporate Controller · Jan 1, 2021 – Jun 7, 2023 · Past |
| Tony Dung Ling Yao Other companies: 4D Molecular Therapeutics, Inc. (Director · Dec 10, 2020 – Dec 15, 2020 · Past) | Director · Mar 27, 2019 – Apr 3, 2019 · Past |
| Abid Ansari | Chief Financial Officer · Mar 27, 2019 – Jun 15, 2020 · Past |
| Alex Kelly | Chief Operating Officer · Since at least Aug 6, 2026 |
| Cassandra Louise Gorsuch | Chief Scientific Officer · Since at least Aug 1, 2026 |
| Cassie Gorsuch | Chief Scientific Officer · Since at least Aug 6, 2026 |
| Cindy Atwell | Chief Development Officer · Since at least Jul 27, 2026 |
| Dario Scimeca | Chief Legal Officer · Since at least Jun 10, 2019 |
| David S Thomson | Chief Operating Officer · Mar 27, 2019 – Jun 23, 2021 · Past |
| Derek Jantz | Chief Scientific Officer, Director · Mar 27, 2019 – Jun 7, 2022 · Past |
| Fayaz Khazi | CEO of Elo Life Systems · Mar 27, 2019 – Jun 7, 2021 · Past |
| Jeff Smith | Chief Research Officer · Since at least Oct 8, 2026 |
| J Jefferson Smith | Chief Research Officer · Since at least Sep 1, 2022 |
| Juli Blanche | Chief People Officer · Since at least Nov 5, 2026 |
| Kevin Buehler | Director · Since at least Nov 8, 2019 |
| Mark Sulkowski | Head Clinical Development Advisor · Since at least Oct 8, 2026 |
| Matthew R Kane | President and CEO, Director · Sep 23, 2019 – Jun 7, 2021 · Past |
| Mei Zhang Lu Burris | Chielf Accounting Officer · Since at least Aug 1, 2026 |
| Naresh Tanna | Chief Financial Officer · Since at least Aug 1, 2026 |
| Neil Leatherbury | Senior Vice President of Chemistry, Manufacturing, and Controls (CMC) · Since at least Oct 8, 2026 |
| Shari Lisa Piré | Director · Since at least Nov 8, 2021 |
| Stanley Frankel | Director · Since at least Apr 12, 2021 |
Log in to ask 6ix AI your own questions about Precision BioSciences, Inc.